Chronic Beryllium Disease: Revealing the Role of Beryllium Ion and Small Peptides Binding to HLA-DP2

Chronic Beryllium (Be) Disease (CBD) is a granulomatous disorder that predominantly affects the lung. The CBD is caused by Be exposure of individuals carrying the HLA-DP2 protein of the major histocompatibility complex class II (MHCII). While the involvement of Be in the development of CBD is obvious and the binding site and the sequence of Be and peptide binding were recently experimentally revealed [1], the interplay between induced conformational changes and the changes of the peptide binding affinity in presence of Be were not investigated. Here we carry out in silico modeling and predict the Be binding to be within the acidic pocket (Glu26, Glu68 and Glu69) present on the HLA-DP2 protein in accordance with the experimental work [1]. In addition, the modeling indicates that the Be ion binds to the HLA-DP2 before the corresponding peptide is able to bind to it. Further analysis of the MD generated trajectories reveals that in the presence of the Be ion in the binding pocket of HLA-DP2, all the different types of peptides induce very similar conformational changes, but their binding affinities are quite different. Since these conformational changes are distinctly different from the changes caused by peptides normally found in the cell in the absence of Be, it can be speculated that CBD can be caused by any peptide in presence of Be ion. However, the affinities of peptides for Be loaded HLA-DP2 were found to depend of their amino acid composition and the peptides carrying acidic group at positions 4 and 7 are among the strongest binders. Thus, it is proposed that CBD is caused by the exposure of Be of an individual carrying the HLA-DP2*0201 allele and that the binding of Be to HLA-DP2 protein alters the conformational and ionization properties of HLA-DP2 such that the binding of a peptide triggers a wrong signaling cascade.

[1]  B. Palmer,et al.  Impaired Function of CTLA-4 in the Lungs of Patients with Chronic Beryllium Disease Contributes to Persistent Inflammation , 2013, The Journal of Immunology.

[2]  Emil Alexov,et al.  BION web server: predicting non-specifically bound surface ions , 2013, Bioinform..

[3]  P. Marrack,et al.  Structural Basis of Chronic Beryllium Disease: Linking Allergic Hypersensitivity and Autoimmunity , 2014, Cell.

[4]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[5]  M. Strand,et al.  Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. , 2011, American journal of respiratory and critical care medicine.

[6]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[7]  B. Scott,et al.  Potential binding modes of beryllium with the class II major histocompatibility complex HLA-DP: a combined theoretical and structural database study. , 2003, Journal of inorganic biochemistry.

[8]  L. Newman,et al.  Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression. , 2011, The Journal of allergy and clinical immunology.

[9]  Peicho Petkov,et al.  HLA‐DP2 binding prediction by molecular dynamics simulations , 2011, Protein science : a publication of the Protein Society.

[10]  Chuan Li,et al.  Continuous development of schemes for parallel computing of the electrostatics in biological systems: Implementation in DelPhi , 2013, J. Comput. Chem..

[11]  E. Alexov,et al.  Calculated protein and proton motions coupled to electron transfer: electron transfer from QA- to QB in bacterial photosynthetic reaction centers. , 1999, Biochemistry.

[12]  T. Gille,et al.  Chronic beryllium disease: azathioprine as a possible alternative to corticosteroid treatment , 2013, European Respiratory Journal.

[13]  Emil Alexov,et al.  The role of protonation states in ligand-receptor recognition and binding. , 2013, Current pharmaceutical design.

[14]  L. Richeldi,et al.  HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. , 1993, Science.

[15]  A. Seidler,et al.  Systematic review: Progression of beryllium sensitization to chronic beryllium disease. , 2012, Occupational medicine.

[16]  Christine R. Schuler,et al.  Long-term efficacy of a program to prevent beryllium disease. , 2013, American Journal of Industrial Medicine.

[17]  J. Kappler,et al.  Identification of Multiple Public TCR Repertoires in Chronic Beryllium Disease , 2014, The Journal of Immunology.

[18]  L. Newman,et al.  Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease. , 2012, Respiratory medicine.

[19]  R. A. Santos,et al.  HLA alleles and HLA-B27 haplotypes associated with susceptibility and severity of ankylosing spondylitis in a Portuguese population. , 2013, Tissue antigens.

[20]  M. Amicosante,et al.  Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. , 2001, Human immunology.

[21]  A. Panchenko,et al.  Predicting the Impact of Missense Mutations on Protein–Protein Binding Affinity , 2014, Journal of chemical theory and computation.

[22]  L. Welch,et al.  Beryllium disease among construction trade workers at Department of Energy nuclear sites. , 2013, American journal of industrial medicine.

[23]  Emil Alexov,et al.  Predicting nonspecific ion binding using DelPhi. , 2012, Biophysical journal.

[24]  Emil Alexov,et al.  Protonation and pK changes in protein–ligand binding , 2013, Quarterly Reviews of Biophysics.

[25]  P. Gregersen,et al.  MHC associations with clinical and autoantibody manifestations in European SLE , 2014, Genes and Immunity.

[26]  Emil Alexov,et al.  Modeling effects of human single nucleotide polymorphisms on protein-protein interactions. , 2009, Biophysical journal.

[27]  L. Newman,et al.  Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Lin Wang,et al.  Analyzing Effects of Naturally Occurring Missense Mutations , 2012, Comput. Math. Methods Medicine.

[29]  S. Dai,et al.  T cell recognition of beryllium. , 2013, Current opinion in immunology.

[30]  Zhe Zhang,et al.  Computational analysis of missense mutations causing Snyder‐Robinson syndrome , 2010, Human mutation.

[31]  M. Strand,et al.  Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry , 2011, Occupational and Environmental Medicine.

[32]  S. Dai,et al.  Structural basis of metal hypersensitivity , 2013, Immunologic research.

[33]  C. Nombela,et al.  Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs , 2004, Immunogenetics.

[34]  E. Alexov,et al.  Incorporating protein conformational flexibility into the calculation of pH-dependent protein properties. , 1997, Biophysical journal.

[35]  L. Boulet,et al.  Genetic Variants in the Major Histocompatibility Complex Class I and Class Ii Genes Are Associated with Diisocyanate-induced Asthma Hhs Public Access Materials and Methods Genotype Distribution and Genetic Models Regulatory Information for Significant Associations , 2022 .

[36]  Yang Gao,et al.  Predicting folding free energy changes upon single point mutations , 2012, Bioinform..

[37]  L. Maier,et al.  Developing Effective Health and Safety Training Materials for Workers in Beryllium-Using Industries , 2013, Journal of occupational and environmental medicine.

[38]  Douglas G. Mack,et al.  Crystal structure of HLA-DP2 and implications for chronic beryllium disease , 2010, Proceedings of the National Academy of Sciences.

[39]  J. Kappler,et al.  Mutagenesis of Beryllium-Specific TCRs Suggests an Unusual Binding Topology for Antigen Recognition , 2011, The Journal of Immunology.

[40]  Benjamin A. Shoemaker,et al.  Cancer Missense Mutations Alter Binding Properties of Proteins and Their Interaction Networks , 2013, PloS one.

[41]  E. Alexov,et al.  Combining conformational flexibility and continuum electrostatics for calculating pK(a)s in proteins. , 2002, Biophysical journal.

[42]  Timothy S. Keizer,et al.  Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells1 , 2006, The Journal of Immunology.

[43]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[44]  L. Newman,et al.  Identification of pathogenic T cells in patients with beryllium-induced lung disease. , 1999, Journal of immunology.

[45]  J. Bill,et al.  Beryllium Presentation to CD4+ T Cells Is Dependent on a Single Amino Acid Residue of the MHC Class II β-Chain1 , 2005, The Journal of Immunology.

[46]  Christine R. Schuler,et al.  Chronic Beryllium Disease, HLA-DPB1, and the DP Peptide Binding Groove , 2011, The Journal of Immunology.

[47]  Radleigh G. Santos,et al.  Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease , 2013, The Journal of experimental medicine.

[48]  Zhe Zhang,et al.  On the role of electrostatics in protein–protein interactions , 2011, Physical biology.

[49]  Irini Doytchinova,et al.  Peptide binding prediction for the human class II MHC allele HLA-DP2: a molecular docking approach , 2011, BMC Structural Biology.